Form 8-K - Current report:
SEC Accession No. 0001558370-20-011292
Filing Date
2020-09-29
Accepted
2020-09-29 07:06:14
Documents
14
Period of Report
2020-09-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K axsm-20200925x8k.htm   iXBRL 8-K 62445
2 EX-99.1 axsm-20200925xex99d1.htm EX-99.1 17264
3 GRAPHIC axsm-20200925xex99d1001.jpg GRAPHIC 4928
  Complete submission text file 0001558370-20-011292.txt   219477

Data Files

Seq Description Document Type Size
4 EX-101.SCH axsm-20200925.xsd EX-101.SCH 3303
5 EX-101.LAB axsm-20200925_lab.xml EX-101.LAB 16159
6 EX-101.PRE axsm-20200925_pre.xml EX-101.PRE 10965
7 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20200925x8k_htm.xml XML 4869
Mailing Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007
Business Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 201206000
SIC: 2834 Pharmaceutical Preparations